A number of clinical trials demonstrated that TRK inhibitors (larotrectinib or entrectinib) have superior therapeutic effect compared with chemotherapy in advanced NSCLC patients with NTRK-positive mutations regardless of tumor type, fusion type and age, with a median progression-free survival (PFS) of 11.2 to 25.8 months [19, 20]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.